Lantibiotics: Promising candidates for future applications in health care

International Journal of Medical Microbiology

Volumn 304, Issue 1, 2014, Pages 51-62

  Dischinger, Jasmin ^a   Basi Chipalu, Shradha ^a   Bierbaum, Gabriele ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Alternative therapeutics; Bacteriocins; Lanthipeptides; Lantibiotics; Multiresistant pathogens; Pharmaceutical applications

Indexed keywords

LANCOVUTIDE; LANTHIONINE; LANTHIPEPTIDE DERIVATIVE; LANTIBIOTIC; POLYPEPTIDE ANTIBIOTIC AGENT; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ACTINOBACTERIA; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; BIOLOGICAL ACTIVITY; CHEMICAL MODIFICATION; CHLAMYDIA; CYCLIZATION; DRUG SYNTHESIS; FIRMICUTES; GENE CLUSTER; GENE CONTROL; HEALTH CARE; HEALTH CARE COST; HUMAN; MEMBRANE DEPOLARIZATION; MEMBRANE POTENTIAL; NONHUMAN; OXIDATION; PROTEIN PROCESSING; PROTEOBACTERIA; SHORT SURVEY; STEREOCHEMISTRY; STREPTOMYCES VENEZUELAE; TRANSPOSON;

ALTERNATIVE THERAPEUTICS; BACTERIOCINS; LANTHIPEPTIDES; LANTIBIOTICS; MULTIRESISTANT PATHOGENS; PHARMACEUTICAL APPLICATIONS;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIOCINS; FOOD PRESERVATIVES; HUMANS;

EID: 84892517022     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2013.09.003     Document Type: Short Survey

References (101)

1. Alen M.F., Neyts J., Süssmuth R.D., Brönstrup M., Schols D. Labyrinthopeptins, a new class of lantibiotics, exhibit potent anti-dengue virus activity. Twenty-Fifth International Conference on Antiviral Research (ICAR) 2012.
2. Appleyard A.N., Choi S., Read D.M., Lightfoot A., Boakes S., Hoffmann A., Chopra I., Bierbaum G., Rudd B.A., Dawson M.J., Cortes J. Dissecting structural and functional diversity of the lantibiotic mersacidin. Chem. Biol. 2009, 29(16):490-498.
3. Arnison P.G., Bibb M.J., Bierbaum G., Bowers A.A., Bugni T.S., Bulaj G., Camarero J.A., Campopiano D.J., Challis G.L., Clardy J., Cotter P.D., Craik D.J., Dawson M., Dittmann E., Donadio S., Dorrestein P.C., Entian K.D., Fischbach M.A., Garavelli J.S., Göransson U., Gruber C.W., Haft D.H., Hemscheidt T.K., Hertweck C., Hill C., Horswill A.R., Jaspars M., Kelly W.L., Klinman J.P., Kuipers O.P., Link A.J., Liu W., Marahiel M.A., Mitchell D.A., Moll G.N., Moore B.S., Müller R., Nair S.K., Nes I.F., Norris G.E., Olivera B.M., Onaka H., Patchett M.L., Piel J., Reaney M.J., Rebuffat S., Ross R.P., Sahl H.G., Schmidt E.W., Selsted M.E., Severinov K., Shen B., Sivonen K., Smith L., Stein T., Süssmuth R.D., Tagg J.R., Tang G.L., Truman A.W., Vederas J.C., Walsh C.T., Walton J.D., Wenzel S.C., Willey J.M., van der Donk W.A. Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat. Prod. Rep. 2013, 30:108-160.
4. Bani-Jaber A., McGuire J., Ayres J.W., Daeschel M.A. Efficacy of the Antimicrobial Peptide Nisin in Emulsifying Oil in Water. J. Food Sci 2000, 65:502-506.
5. Bierbaum G., Sahl H.G. Lantibiotics: mode of action, biosynthesis and bioengineering. Curr. Pharm. Biotechnol. 2009, 10:2-18.
6. Birri D.J., Brede D.A., Nes I.F. Salivaricin D, a novel intrinsically trypsin-resistant lantibiotic from Streptococcus salivarius 5M6c isolated from a healthy infant. Appl. Environ. Microbiol. 2012, 78:402-410.
7. Boakes S., Appleyard A.N., Cortes J., Dawson M.J. Organization of the biosynthetic genes encoding deoxyactagardine B (DAB), a new lantibiotic produced by Actinoplanes liguriae NCIMB41362. J. Antibiot. 2010, 63:351-358.
8. Boakes S., Wadman S. The therapeutic potential of lantibiotics. Innovation in Pharmaceutical Technology: Drug Discovery and Development (IPT 27) 2008, 22-25.
9. 2+ ions on the activity of lantibiotics containing a mersacidin-like lipid II binding motif. Appl. Environ. Microbiol. 2009, 75:4427-4434.
10. Bonelli R.R., Schneider T., Sahl H.G., Wiedemann I. Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode-of-action studies. Antimicrob. Agents Chemother. 2006, 50:1449-1457.
11. Bosma T., Kuipers A., Bulten E., de Vries L., Rink R., Moll G.N. Bacterial display and screening of posttranslationally thioether-stabilized peptides. Appl. Environ. Microbiol. 2011, 7:6794-6801.
12. Bower C.K., Bothwell M.K., McGuire J. Lantibiotics as surface active agents for biomedical applications. Colloids Surf. B Biointerfaces 2001, 22:259-265.
13. Breukink E., van Heusden H.E., Vollmerhaus P.J., Swiezewska E., Brunner L., Walker S., Heck A.J., de Kruijff B. Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes. Biol. Chem. 2003, 278:19898-19903.
14. Broetz H., Josten M., Wiedemann I., Schneider U., Götz F., Bierbaum G., Sahl H.G. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin epidermin and other lantibiotics. Mol. Microbiol. 1998, 30:317-327.
15. Cao L.T., Wu J.Q., Xie F., Hu S.H., Mo Y. Efficacy of nisin in treatment of clinical mastitis in lactating dairy cows. J. Dairy Sci. 2007, 90:3980-3985.
16. Castiglione, Lazzarini F., Carrano A., Corti L., Ciciliato E., Gastaldo I., Candiani L., Losi P., Marinelli D., Selva F., Parenti E. Determining the structure and mode of action of microbisporicin a potent lantibiotic active against multiresistant pathogens. Chem. Biol. 2008, 15:22-31.
17. Chatterjee C., Paul M., Xie L., van der Donk W.A. Biosynthesis and mode of action of lantibiotics. Chem. Rev. 2005, 105:633-684.
18. Clara A., Gupta S.M., Reddy K.V.R. Spermicidal activity of Nisin: in vitro and in vitro studies. Contraception 2004, 69:333-342.
19. Cloutier M.M., Guernsey L., Mattes P., Koeppen B. Duramycin enhances chloride secretion in airway epithelium. Am. J. Physiol. 1990, 259:450-454.
20. Cotter P.D., Deegan L.H., Lawton E.M., Draper L.A., O'Connor P.M., Hill C., Ross R.P. Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design. Mol. Microbiol. 2006, 62:735-747.
21. Daly K.M., Upton M., Sandiford S.K., Draper L.A., Wescombe P.A., Jack R.W., O'Connor P.M., Rossney A., Götz F., Hill C., Cotter P.D., Ross R.P., Tagg J.R. Production of the Bsa lantibiotic by community-acquired Staphylococcus aureus strains. J. Bacteriol. 2010, 192:1131-1142.
22. Delves-Broughton J., Blackburn P., Evans R.J., Hugenholtz J. Applications of the bacteriocin, nisin. Antonie Van Leeuwenhoek 1996, 69:193-202.
23. Denny C.B., Sharpe L.E., Bohrer C.W. Effects of tylosin and nisin on canned food spoilage bacteria. Appl. Microbiol. 1961, 9:108-110.
24. Dierksen K.P., Moore C.J., Inglis M., Wescombe P.A., Tagg J.R. The effect of ingestion of milk supplemented with salivaricin A-producing Streptococcus salivarius on the bacteriocin-like inhibitory activity of streptococcal populations on the tongue. FEMS Microbiol. Ecol. 2007, 59:584-591.
25. Dischinger J., Wiedemann I., Bierbaum G., Sahl H.G. Lantibiotics. Handbook of Biologically Active Peptides 2013, 119-128. Academic Press Incorporation, Elsevier, San Diego, USA. second ed. J. Abba Kastin (Ed.).
26. Fagundes P., Ceotto H., Potter A., Vasconcelos de P., Maria A., Brede D., Nes I.F., Bastos M. Hyicin 3682, a bioactive peptide produced by Staphylococcus hyicus 3682 with potential applications for food preservation. Res. Microbiol. 2011, 162:1052-1059.
27. Fernandez L., Delgado S., Herrero H., Maldonado A., Rodriguez J.M. The bacteriocin nisin, an effective agent for the treatment of staphylococcal mastitis during lactation. J. Hum. Lact. 2008, 24:311-316.
28. Field D., Begley M., O'Connor P.M., Daly K.M., Hugenholtz F., Cotter P.D., Hill C., Ross R.P. Bioengineered nisin A derivatives with enhanced activity against both Grampositive and Gram- negative pathogens. PLoS ONE 2012, 7:e46884.
29. Fontana M.B., de Bastos M.C., Brandelli A. Bacteriocins Pep5 and epidermin inhibit Staphylococcus epidermidis adhesion to catheters. Curr. Microbiol. 2006, 52:350-353.
30. Garg N., Tang W., Goto Y., Nair S.K., van der Donk W.A. Lantibiotics from Geobacillus thermodenitrificans. PNAS 2012, 109:5241-5246.
31. Goto Y., Li B., Claesen J., Shi Y., Bibb M.J., van der Donk W.A. Discovery of unique lanthionine synthetases reveals new mechanistic and evolutionary insights. PLoS Biol. 2010, 8:e1000339.
32. Grasemann H. New developments in pharmaceutical treatments for cystic fibrosis. Curr. Pharm. Des. 2012, 18:613.
33. Grasemann H., Stehling F., Brunar H., Widmann R., Laliberte T.W., Molina L., Döring G., Ratjen F. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 2007, 131:1461-1466.
34. Gratia A. Sur un remarquable example d'antagonisme entre deux souches de colibacille. Comp. Rend. Soc. Biol 1925, 93:1040-1041.
35. Gut I.M., Blanke S.R., van der Donk W.A. Mechanism of inhibition of Bacillus anthracis spore outgrowth by the lantibiotic nisin. ACS Chem. Biol. 2011, 6:744-752.
36. Hasper H.E., Kruijff B., de Breukink E. Assembly and stability of nisin-lipid II pores. Biochemistry 2004, 43:11567-11575.
37. Hosoda K., Ohya M., Kohno T., Maeda T., Endo S., Wakamatsu K. Structure determination of an immunopotentiator peptide, cinnamycin, complexed with lysophosphatidylethanolamine by 1H-NMR1. J. Biochem. 1996, 119:226-230.
38. Hsu S.T., Breukink E., Tischenko E., Lutters M.A., de Kruijff B., Kaptein R., Bonvin A.M., van Nuland N.A. The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat. Struct. Mol. Biol. 2004, 11:963-967.
39. Jabes D., Brunati C., Guglierame S., Donadio S. In vitro antibacterial profile of the new lantibiotic NAI-107. 49th Annual Meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy 2009.
40. Kido Y., Hamakado T., Yoshida T., Anno M., Motoki Y., Wakamiya T., Shiba T. Isolation and characterization of ancovenin, a new inhibitor of angiotensin I converting enzyme, produced by actinomycetes. J. Antibiot. 1983, 36:1295-1299.
41. Klaenhammer T.R. Bacteriocins of lactic acid bacteria. Biochimie 1988, 70:337-349.
42. Kluskens L.D., Kuipers A., Rink R., de Boef E., Fekken S., Driessen A.J., Kuipers O.P., Moll G.N. Post-translational modification of therapeutic peptides by NisB, the dehydratase of the lantibiotic nisin. Biochemistry 2005, 44:12827-12834.
43. Knerr P.J., van der Donk W.A. Discovery, biosynthesis, and engineering of lantipeptides. Annu. Rev. Biochem. 2012, 81:479-505.
44. Kodani S., Hudson M.E., Durrant M.C., Buttner M.J., Nodwell J.R., Willey J.M. The SapB morphogen is a lantibiotic-like peptide derived from the product of the developmental gene ramS in Streptomyces coelicolor. PNAS 2004, 101:11448-11453.
45. Kodani S., Lodato M.A., Durrant M.C., Picart F., Willey J.M. SapTa lanthionine-containing peptide involved in aerial hyphae formation in the streptomycetes. Mol. Microbiol. 2005, 58:1368-1380.
46. Kordel M., Benz R., Sahl H.G. Mode of action of the staphylococcin like peptide Pep 5: voltage-dependent depolarization of bacterial and artificial membranes. J. Bacteriol. 1988, 170:84-88.
47. Krawczyk B., Voller G.H., Voller J., Ensle P., Suessmuth R.D. Curvopeptin: a new lanthionine-containing class III lantibiotic and its co-substrate promiscuous synthetase. ChemBioChem 2012, 13:2065-2071.
48. Kruszewska D., Sahl H.-G., Bierbaum G., Pag U., Hynes S.O., Ljungh A. Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J. Antimicrob. Chemother. 2004, 54:648-653.
49. Kuipers O.P., Beerthuyzen M.M., Ruyter P.G., de Luesink E.J., de Vos W.M. Autoregulation of nisin biosynthesis in Lactococcus lactis by signal transduction. J. Biol. Chem. 1995, 270:27299-27304.
50. Levengood M.R., Patton G.C., van der Donk W.A. The leader peptide is not required for posttranslational modification by lacticin 481 synthetase. J. Am. Chem. Soc. 2007, 129:10314-10315.
51. Li B., Sher D., Kelly L., Shi Y., Huang K., Knerr P.J., Joewono I., Rusch D., Chisholm S.W., van der Donk W.A. Catalytic promiscuity in the biosynthesis of cyclic peptide secondary metabolites in planktonic marine cyanobacteria. PNAS 2010, 107:10430-10435.
52. Li P., Li X., Saravanan R., Li C.M., Leong S.S.J. Antimicrobial macromolecules: synthesis methods and future applications. RSC Adv. 2012, 2:4031-4044.
53. Lohans C.T., Huang Z., van Belkum M.J., Giroud M., Sit C.S., Steels E.M., Zheng J., Whittal R.M., McMullen L.M., Vederas J.C. Structural characterization of the highly cyclized lantibiotic Paenicidin A via a partial desulfurization/reduction strategy. J. Am. Chem. Soc. 2012, 134:19540-19543.
54. Makino A., Baba T., Fujimoto K., Iwamoto K., Yano Y., Terada N., Ohno S., Sato S.B., Ohta A., Umeda M., Matsuzaki K., Kobayashi T. Cinnamycin (Ro 09-0198) promotes cell binding and toxicity by inducing transbilayer lipid movement. J. Biol. Chem. 2003, 278:3204-3209.
55. Märki F., Hänni E., Fredenhagen A., van Oostrum J. Mode of action of the lanthionine-containing peptide antibiotics duramycin, duramycin B and C, and cinnamycin as indirect inhibitors of phospholipase A2. Biochem. Pharmacol. 1991, 42:2027-2035.
56. Mantovani H.C., Hu H., Worobo R.W., Russell J.B. Bovicin HC5, a bacteriocin from Streptococcus bovis HC5. Microbiology 2002, 148:3347-3352.
57. Mantovani H.C., Russell J.B. Bovicin HC5 a lantibiotic produced by Streptococcus bovis HC5, catalyzes the efflux of intracellular potassium but not ATP. Antimicrob. Agents Chemother. 2008, 52:2247-2249.
58. Marsh A., O'Sullivan O., Ross R.P., Cotter P., Hill C. In silico analysis highlights the frequency and diversity of type 1 lantibiotic gene clusters in genome sequenced bacteria. BMC Genom. 2010, 11:679.
59. Meindl K., Schmiederer T., Schneider K., Reicke A., Butz D., Keller S., Gühring H., Vértesy L., Wink J., Hoffmann H., Brönstrup M., Sheldrick G.M., Süssmuth R.D. Labyrinthopeptins: a new class of carbacyclic lantibiotics. Angew. Chem. 2010, 49:1151-1154.
60. Morgan S.M., O'Connor P.M., Cotter P.D., Ross R.P., Hill C. Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations. Antimicrob. Agents Chemother. 2005, 49:2606-2611.
61. Müller W.M., Ensle P., Krawczyk B., Suessmuth R.D. Leader peptide-directed processing of labyrinthopeptin A2 precursor peptide by the modifying enzyme LabKC. Biochemistry 2011, 50:8362-8373.
62. Müller W.M., Schmiederer T., Ensle P., Suessmuth R.D. In vitro biosynthesis of the prepeptide of type-III lantibiotic labyrinthopeptin A2 including formation of a CC bond as a post-translational modification. Angew. Chem. 2010, 49:2436-2440.
63. Nagao J., Morinaga Y., Islam M.R., Asaduzzaman S.M., Aso Y., Nakayama J., Sonomoto K. Mapping and identification of the region and secondary structure required for the maturation of the nukacin ISK-1 prepeptide. Peptides 2009, 30:1412-1420.
64. Naruse N., Tenmyo O., Tomita K., Konishi M., Miyaki T., Kawaguchi H., Shiba T. Lanthiopeptin, a new peptide antibiotic. Production, isolation and properties of lanthiopeptin. J. Antibiot. 1989, 42:837-845.
65. Oliynyk I., Varelogianni G., Roomans G.M., Johannesson M. Effect of duramycin on chloride transport and intracellular calcium concentration in cystic fibrosis and non-cystic fibrosis epithelia. A.P.M.I.S 2010, 118:982-990.
66. Ösapay G., Prokai L., Kim H.S., Medzihradszky K.F., Coy D.H., Liapakis G., Reisine T., Melacini G., Zhu Q., Wang S.H., Mattern R.H., Goodman M. Lanthionine-somatostatin analogs: synthesis, characterization, biological activity, and enzymatic stability studies. J. Med. Chem. 1997, 40:2241-2251.
67. Paul M., Patton G.C., van der Donk W.A. Mutants of the zinc ligands of lacticin 481 synthetase retain dehydration activity but have impaired cyclization activity. Biochemistry 2007, 46:6268-6276.
68. Rew Y., Malkmus S., Svensson C., Yaksh T.L., Chung N.N., Schiller P.W., Cassel J.A., DeHaven R.N., Taulane J.P., Goodman M. Synthesis and biological activities of cyclic lanthionine enkephalin analogues: delta-opioid receptor selective ligands. J. Med. Chem. 2002, 45:3746-3754.
69. Rink R., Kuipers A., de Boef E., Leenhouts K.J., Driessen A.J., Moll G.N., Kuipers O.P. Lantibiotic structures as guidelines for the design of peptides that can be modified by lantibiotic enzymes. Biochemistry 2005, 44:8873-8882.
70. Roberts M., Hladky S.B., Pickles R.J., Cuthbert A.W. Stimulation of sodium transport by duramycin in cultured human colonic epithelia. J. Pharmacol. Exp. Ther. 1991, 259:1050-1058.
71. Rodríguez-Valera F., Juez J., Kushner D.J. Halocins: salt dependent bacteriocins produced by extremely halophilic rods. Can. J. Microbiol. 1982, 28:151-154.
72. Rogers L.A. The inhibiting effect of Streptococcus lactis on Lactobacillus bulgaricus. J. Bacteriol. 1928, 16:321-325.
73. Ross A.C., Vederas J.C. Fundamental functionality: recent developments in understanding the structure-activity relationships of lantibiotic peptides. J. Antibiot. (Tokyo) 2010, 64:27-34.
74. Sahl H.G., Bierbaum G. Lantibiotics: biosynthesis and biological activities of uniquely modified peptides from Gram-positive bacteria. Annu. Rev. Microbiol. 1998, 52:41-79.
75. Sahl H.G., Brandis H. Mode of action of the staphylococcin-like peptide Pep 5 and culture conditions affecting its activity. Zentralbl. Bakteriol. Mikrobiol. Hyg. 1982, 252:166-175.
76. Sandiford S., Kay P., Upton M. The use of antimicrobial peptides in the prevention of biofilm forming S. epidermidis strains associated with orthopaedic infection. Seventh SICOT/SIROT Annual International Conference and SOF Ortopediveckan 2010.
77. Sawa N., Wilaipun P., Kinoshita S., Zendo T., Leelawatcharamas V., Nakayama J., Sonomoto K. Isolation and characterization of enterocin W a novel two-peptide lantibiotic produced by Enterococcus faecalis NKR-4-1. Appl. Environ. Microbiol. 2012, 78:900-903.
78. Schmitz S., Hoffmann A., Szekat C., Rudd B., Bierbaum G. The lantibiotic mersacidin is an autoinducing peptide. Appl. Environ. Microbiol. 2006, 72:7270-7277.
79. Schnell N., Entian K.D., Schneider U., Götz F., Zähner H., Kellner R., Jung G. Prepeptide sequence of epidermin, a ribosomally synthesized antibiotic with four sulphide-rings. Nature 1988, 333:276-278.
80. Siezen R.J., Kuipers O.P., de Vos W.M. Comparison of lantibiotic gene clusters and encoded proteins. Antonie Van Leeuwenhoek 1996, 69:171-184.
81. Simone M., Monciardini P., Gaspari E., Donadio S., Maffioli S.I. Isolation and characterization of NAI-802, a new lantibiotic produced by two different Actinoplanes strains. J. Antibiot. (Tokyo) 2013, 66:73-78.
82. Stevens K.A., Sheldon B.W., Klapes N.A., Klaenhammer T.R. Nisin treatment for inactivation of Salmonella species and other Gram-negative bacteria. Appl. Environ. Microbiol. 1991, 57:3613-3615.
83. Suda S., Cotter P.D., Hill C., Ross R.P. Lacticin 3147 - biosynthesis, molecular analysis, immunity, bioengineering and applications. Curr. Protein Pept. Sci. 2011, 13:193-204.
84. Szekat C., Jack R.W., Skutlarek D., Färber H., Bierbaum G. Construction of an expression system for site-directed mutagenesis of the lantibiotic mersacidin. Appl. Environ. Microbiol. 2003, 69:3777-3783.
85. Tagg J.R., Dajani A.S., Wannamaker L.W. Bacteriocins of Gram-positive bacteria. Bacteriol. Rev. 1976, 40:722-756.
86. Tang W., van der Donk W.A. Structural characterization of four prochlorosins: a novel class of lantipeptides produced by planktonic marine cyanobacteria. Biochemistry 2012, 51:4271-4279.
87. Tang W., van der Donk W.A. The sequence of the enterococcal cytolysin imparts unusual lanthionine stereochemistry. Nat. Chem. Biol. 2013, (2013 Jan 13 [Epub ahead of print] PubMed PMID: 23314913). 10.1038/nchembio.1162.
88. Teng Y., Zhao W., Qian C., Li O., Zhu L., Wu X. Gene cluster analysis for the biosynthesis of elgicins, novel lantibiotics produced by Paenibacillus elgii B69. BMC Microbiol. 2012, 12:45.
89. van Heel A.J., Montalban-Lopez M., Kuipers O.P. Evaluating the feasibility of lantibiotics as an alternative therapy against bacterial infections in humans. Expert Opin. Drug Metab. Toxicol. 2011, 7:675-680.
90. van Kraaij C., de Vos W.M., Siezen R., Kuipers O.P. Lantibiotics: biosynthesis mode of action and applications. Nat. Prod. Rep. 1999, 16:575-587.
91. Voeller G.H., Krawczyk J.M., Pesic A., Krawczyk B., Nachtigall J., Süssmuth R.D. Characterization of new Class III Lantibiotics-Erythreapeptin, Avermipeptin and Griseopeptin from Saccharopolyspora erythraea, Streptomyces avermitilis and Streptomyces griseus demonstrates stepwise N-Terminal leader processing. ChemBioChem 2012, 13(8):1174-1183.
92. Wang H., van der Donk W.A. Biosynthesis of the class III lantipeptide catenulipeptin. ACS Chem. Biol. 2012, 7:1529-1535.
93. Wescombe P.A., Dyet K.H., Dierksen K.P., Power D.A., Jack R.W., Burton J.P., Inglis M.A., Wescombe A.L., Tagg J.R. Salivaricin G32, a homolog of the prototype Streptococcus pyogenes nisin-like lantibiotic SA-FF22, produced by the commensal species Streptococcus salivarius. Int. J. Microbiol. 2012, (in press). 10.1155/2012/738503.
94. Wiedemann I., Benz R., Sahl H.G. Lipid II-mediated pore formation by the peptide antibiotic nisin: a black lipid membrane study. J. Bacteriol. 2004, 186:3259-3261.
95. Wiedemann I., Böttiger T., Bonelli R.R., Wiese A., Hagge S.O., Gutsmann T., Seydel U., Deegan L., Hill C., Ross P., Sahl H.G. The mode of action of the lantibiotic lacticin 3147 - a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol. Microbiol. 2006, 61:285-296.
96. Wiedemann I., Breukink E., van Kraaij C., Kuipers O.P., Bierbaum G., Kruijff B., de Sahl H.G. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J. Biol. Chem. 2001, 276:1772-1779.
97. Willey J.M., van der Donk W.A. Lantibiotics: peptides of diverse structure and function. Ann. Rev. Microbiol. 2007, 61:477-501.
98. Willey J.M., Willems A., Kodani S., Nodwell J.R. Morphogenetic surfactants and their role in the formation of aerial hyphae in Streptomyces coelicolor. Mol. Microbiol. 2006, 59:731-742.
99. Wilson-Stanford S., Smith L. Commercial development and application of type A lantibiotics. Recent Pat. Antiinfect. Drug Discov. 2011, 6:175-185.
100. Yonezawa H., Kuramitsu H.K. Genetic analysis of a unique bacteriocin, Smb, produced by Streptococcus mutans GS5. Antimicrob. Agents Chemother. 2005, 49:541-548.
101. Zaehner, H., Goetz, F., Hoerner, T., Werner, R.G., Allgaier, H., Jung, G., Kellner, R., 1998. New peptide antibiotic gallidermin is produced by Staphylococcus gallinarum and used esp. for treating eczema, impetigo, cellulitis and acne. U.S. patent 5,843,709-A.